Centessa Pharmaceuticals plc announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares at $21.50 per ADS, expecting to raise approximately $250 million. The offering is set to close on November 14, 2025, with underwriters having an option to purchase additional ADSs. Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are acting as joint book-running managers, while Oppenheimer & Co., Truist Securities, and LifeSci Capital are co-lead managers. The ADSs are being offered under a registration statement filed with the SEC. Centessa aims to develop transformational medicines through its orexin receptor 2 agonist program for various disorders.

Read more at GlobeNewswire: Centessa Pharmaceuticals Announces Pricing of $250,000,000